Roivant CEO Resists Inventory Breakdown For $31 Million Launch As December Sales Face Drag
Pharmacies bought ahead of patient use in September, and management expects stocking to modestly depress December sales.
Roivant Sciences, which develops and commercializes medicines through drug-focused subsidiaries, booked $31 million in LISRAYA launch revenue, but pharmacy stocking helped that total and is expected to modestly depress December sales. On the company's earnings call Monday, Chief Executive Officer Matt Gline resisted analysts' requests to separate inventory purchases from patient use.
Five Weeks, Two Sales Measures
The distinction matters because Roivant books sales when specialty pharmacies purchase the drug, rather than when patients receive it. The September quarter captured five weeks of sales following LISRAYA's August FDA approval for dermatomyositis, according to the company's business update.
A Jefferies analyst asked whether inventory represented most of the $31 million, given the hundreds of patients receiving paid treatment at quarter-end. Gline declined to supply that reconciliation: "we're not going to break out the specifics of how these numbers add up right now."
Gline argued that moving the reporting cutoff by a day or several days could substantially change the relationship between prescriptions and paid prescriptions during such a short launch period. He said pharmacies had held a meaningful quantity of undispensed medicine at September 30, all of which had reached patients by the call.
The company ships against pharmacy orders, Gline said, rather than requiring pharmacies to maintain inventory. He expects the stocking effect to become irrelevant entering next year.
Paid Patients And Coverage Restrictions
By Monday's call, many hundreds of patients were receiving paid treatment, compared with hundreds at quarter-end. Gline also told a JPMorgan analyst that many hundreds of prescribers had written prescriptions—a separate measure of the launch's reach.
Responding to a Leerink Partners analyst, Gline said the company's bridge program does not count toward sales. He described access as relatively straightforward so far, but warned that insurers were still putting coverage controls in place. Some national plans require patients to have tried a systemic immunosuppressant; others impose tougher restrictions.
Gline said prescribing spans patients switching from intravenous immunoglobulin, steroids and immunosuppressants, as well as newly diagnosed patients. The mix varies by practice.
Former trial participants do not explain a concentrated surge in demand, Gline said. The U.S. trial population numbered in the tens, and some participants faced a substantial gap between completing the study and approval. He said there had been no U.S. expanded-access program or defined transition into commercial treatment; some former participants were taking the drug, while others had yet to start.
A Launch Alongside Pipeline Decisions
Roivant's subsidiary model places individual drug programs in businesses it calls Vants. Its work extends beyond LISRAYA to the autoimmune-disease antibody IMVT-1402 and the inhaled pulmonary-hypertension candidate mosliciguat.
Gline told a Citi analyst that Roivant was unlikely to advance IMVT-1402 in Sjögren's beyond its ongoing mid-stage study. He cited competitors' experience, including an unsuccessful Argenix futility analysis involving 500 patients, J&J's dose-response findings, Novartis' FDA discussions and Amgen's results.
Roivant plans to finish its study and could reconsider if the findings surprise, Gline said. Expanding that trial or starting a late-stage study now had been part of its timetable, but he said the competitive evidence no longer justified that step.
Roivant's December 9 investor day is set to include discussion of the commercial opportunities in non-infectious uveitis and difficult-to-treat rheumatoid arthritis.
Sources
- Roivant Sciences GAAP EPS of -$0.27 beats by $0.09, revenue of $35.12M beats by $31.01M (ROIV:NASDAQ) | Seeking Alpha — seekingalpha.com
- Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘ — Yahoo Finance
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates — Yahoo Finance
- Roivant Reports Financial Results for the Second Quarter — globenewswire.com
- Immunovant Provides Corporate Updates and Reports Financial — globenewswire.com